TN2012000531A1 - Substituted heterocyclyl benzyl pyrazoles, and use thereof - Google Patents

Substituted heterocyclyl benzyl pyrazoles, and use thereof

Info

Publication number
TN2012000531A1
TN2012000531A1 TNP2012000531A TN2012000531A TN2012000531A1 TN 2012000531 A1 TN2012000531 A1 TN 2012000531A1 TN P2012000531 A TNP2012000531 A TN P2012000531A TN 2012000531 A TN2012000531 A TN 2012000531A TN 2012000531 A1 TN2012000531 A1 TN 2012000531A1
Authority
TN
Tunisia
Prior art keywords
diseases
substituted heterocyclyl
benzyl
prevention
treatment
Prior art date
Application number
TNP2012000531A
Other languages
English (en)
Inventor
Michael Härter
Hartmut Beck
Susanne Greschat-Schade
Peter Ellinghaus
Kerstin Unterschemman
Joachim Schuhmacher
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2012000531(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of TN2012000531A1 publication Critical patent/TN2012000531A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2012000531A 2010-05-08 2012-11-07 Substituted heterocyclyl benzyl pyrazoles, and use thereof TN2012000531A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08
PCT/EP2011/057021 WO2011141326A1 (de) 2010-05-08 2011-05-03 Substituierte heterocyclylbenzyl-pyrazole und ihre verwendung

Publications (1)

Publication Number Publication Date
TN2012000531A1 true TN2012000531A1 (en) 2014-04-01

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2012000531A TN2012000531A1 (en) 2010-05-08 2012-11-07 Substituted heterocyclyl benzyl pyrazoles, and use thereof

Country Status (26)

Country Link
US (2) US20130172311A1 (OSRAM)
EP (1) EP2569312B1 (OSRAM)
JP (1) JP5727002B2 (OSRAM)
KR (1) KR20130108997A (OSRAM)
CN (1) CN103003269B (OSRAM)
AR (1) AR081368A1 (OSRAM)
AU (1) AU2011252223A1 (OSRAM)
BR (1) BR112012028651A2 (OSRAM)
CA (1) CA2798375A1 (OSRAM)
CO (1) CO6640218A2 (OSRAM)
CR (1) CR20120570A (OSRAM)
CU (1) CU20120157A7 (OSRAM)
DO (1) DOP2012000284A (OSRAM)
EA (1) EA201291167A1 (OSRAM)
EC (1) ECSP12012288A (OSRAM)
ES (1) ES2462522T3 (OSRAM)
IL (1) IL222851A0 (OSRAM)
MA (1) MA34939B1 (OSRAM)
MX (1) MX2012012960A (OSRAM)
PE (1) PE20130228A1 (OSRAM)
PH (1) PH12012502202A1 (OSRAM)
SG (1) SG185459A1 (OSRAM)
TN (1) TN2012000531A1 (OSRAM)
TW (1) TW201200510A (OSRAM)
UY (1) UY33369A (OSRAM)
WO (1) WO2011141326A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155904A2 (en) * 2007-05-01 2010-02-24 Hill's Pet Nutrition Inc. Methods and compositions for diagnosing osteoarthritis in a feline
KR20100016617A (ko) * 2007-05-18 2010-02-12 바이엘 쉐링 파마 악티엔게젤샤프트 과증식성 장애 및 혈관형성 관련 질환의 치료에 유용한 저산소증 유도성 인자 （ｈｉｆ）의 억제제
CN103003269B (zh) * 2010-05-08 2015-11-25 拜耳知识产权有限责任公司 取代的杂环基苄基吡唑及其用途
DK2867230T3 (da) 2012-07-02 2020-04-14 Monsanto Technology Llc Fremgangsmåde til fremstilling af 3,5-disubstitueret 1,2,4-oxadiazoler
RU2698197C2 (ru) 2012-08-24 2019-08-23 Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем Гетероциклические модуляторы активности hif для лечения заболеваний
US20140073634A1 (en) * 2012-08-24 2014-03-13 Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center Heterocyclic modulators of hif activity for treatment of disease
WO2014031933A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
DK3110420T3 (da) 2014-02-25 2019-05-13 Board Of Regents Univ Of Texas System Salte af heterocykliske modulatorer af hif-aktivitet til behandling af sygdomme
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
WO2018131657A1 (ja) * 2017-01-13 2018-07-19 日産化学工業株式会社 芳香族ジアミン化合物前駆体の製造方法
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用
WO2025096654A1 (en) * 2023-10-30 2025-05-08 Pretzel Therapeutics, Inc. Compositions and inhibitors of polrmt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
WO2004089303A2 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
KR20100016617A (ko) * 2007-05-18 2010-02-12 바이엘 쉐링 파마 악티엔게젤샤프트 과증식성 장애 및 혈관형성 관련 질환의 치료에 유용한 저산소증 유도성 인자 （ｈｉｆ）의 억제제
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
WO2010054764A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heteroaromatische verbindungen zur verwendung als hif-inhibitoren
HRP20150341T1 (hr) * 2008-11-14 2015-05-08 Bayer Intellectual Property Gmbh Heterocikliäśki supstituirani spojevi arila kao inhibitori hif
EP2202232A1 (en) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
US8389509B2 (en) 2009-01-23 2013-03-05 Bristol-Myers Squibb Company Substituted pyrazole compounds
CN103003269B (zh) * 2010-05-08 2015-11-25 拜耳知识产权有限责任公司 取代的杂环基苄基吡唑及其用途

Also Published As

Publication number Publication date
CO6640218A2 (es) 2013-03-22
MX2012012960A (es) 2012-12-17
US8470811B2 (en) 2013-06-25
PH12012502202A1 (en) 2013-02-04
EP2569312A1 (de) 2013-03-20
EA201291167A1 (ru) 2013-05-30
BR112012028651A2 (pt) 2016-08-09
DOP2012000284A (es) 2013-03-31
SG185459A1 (en) 2012-12-28
KR20130108997A (ko) 2013-10-07
IL222851A0 (en) 2012-12-31
JP2013526497A (ja) 2013-06-24
CU20120157A7 (es) 2013-03-27
EP2569312B1 (de) 2014-03-26
PE20130228A1 (es) 2013-03-15
US20120028950A1 (en) 2012-02-02
US20130172311A1 (en) 2013-07-04
CN103003269B (zh) 2015-11-25
UY33369A (es) 2011-12-01
JP5727002B2 (ja) 2015-06-03
ECSP12012288A (es) 2012-12-28
AR081368A1 (es) 2012-08-29
TW201200510A (en) 2012-01-01
WO2011141326A1 (de) 2011-11-17
CN103003269A (zh) 2013-03-27
MA34939B1 (fr) 2014-03-01
AU2011252223A1 (en) 2012-12-06
ES2462522T3 (es) 2014-05-23
CR20120570A (es) 2013-04-22
CA2798375A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
TN2012000531A1 (en) Substituted heterocyclyl benzyl pyrazoles, and use thereof
MY160004A (en) Heterocyclically substituted aryl compounds as hif inhibitors
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MY169980A (en) Bisaryl-linked aryltriazolones and their use
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
AU2011328009A8 (en) Compounds and methods for treating pain
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
HK1198869A1 (en) Combination treatments for hepatitis c
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
TN2014000320A1 (en) Substituted phenylimidazopyrazoles and use thereof
TN2013000462A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2012012905A (es) Hidroxialquilbencilpirazoles y su uso para tratamiento de enfermedades hiperproliferativas y angiogenicas.
NZ754706A (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MD20160066A2 (ro) Modulatoare alosterice pozitive ale receptorului nicotinic acetilcolinic
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
WO2012006585A3 (en) Use of interleukin-15 to treat cardiovascular diseases
EA201590350A1 (ru) Комбинации с пептидом с циклизованной основной цепью
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
UA112981C2 (uk) Варіант людського gdnf
UA103784C2 (ru) Гетероциклически замещенные арильные соединения как ингибиторы гиф
UA104730C2 (en) Isoquinolinone derivatives as nk3 antagonists
HK1229697A1 (en) Synergistic bacterial compositions and methods of production and use thereof